Predictors of response to erenumab after 12 months of treatment

被引:34
作者
Baraldi, Carlo [1 ]
Lo Castro, Flavia [2 ]
Cainazzo, Maria Michela [3 ]
Pani, Luca [3 ,4 ,5 ,6 ]
Guerzoni, Simona [3 ]
机构
[1] Univ Modena & Reggio Emilia, Dept Biomed Metab & Neural Sci, PhD Sch Neurosci, Modena, Italy
[2] Univ Modena & Reggio Emilia, Dept Biomed Metab & Neural Sci, Postgrad Sch Pharmacol & Clin Toxicol, Modena, Italy
[3] Univ Modena & Reggio Emilia, Dept Biomed Metab & Neural Sci, Med Toxicol Headache & Drug Abuse Res Ctr, Modena, Italy
[4] Univ Modena & Reggio Emilia, Dept Biomed Metab & Neural Sci, Pharmacol Unit, Modena, Italy
[5] Univ Miami, Dept Psychiat & Behav Sci, Miami, FL USA
[6] VeraSci, Durham, NC USA
来源
BRAIN AND BEHAVIOR | 2021年 / 11卷 / 08期
关键词
chronic migraine; erenumab; medication overuse-headache; predictors of response; real-life setting; MEDICATION-OVERUSE HEADACHE; CHRONIC MIGRAINE; PATHOPHYSIOLOGY;
D O I
10.1002/brb3.2260
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
Objective Erenumab is a monoclonal antibody acting against calcitonin gene-related peptide receptor and approved for the preventive treatment of chronic migraine. The aim of the present study is to identify clinical predictors of good response in patients with chronic migraine and medication overuse-headache. Material and methods This was a retrospective single-center not funded study. Enrolled patients were affected by chronic migraine and medication overuse-headache treated with erenumab monthly, up to 1 year. At 1 year, patients were classified as good responders if they displayed a >= 50% reduction in the number of headache days per months compared to the baseline. Results After 1 year, a significant improvement in the number of headache days per months, analgesic consumption, 6-items headache impact test, and migraine disability assessment questionnaire scores were obtained compared to the baseline. Patients who obtained a >= 50% reduction in the number of headache days per month compared to the baseline displayed a longer history of medication overuse-headache, a higher number of painkillers taken per month at the baseline and a higher number of failed preventive treatments in the past. Conclusions Patients with longer medication overuse-headache duration, higher analgesic intake, and a higher number of previous preventive treatment failures may receive less benefit with erenumab.
引用
收藏
页数:8
相关论文
共 30 条
[1]   Short and Mid-Term Predictors of Response to OnabotulinumtoxinA: Real-Life Experience Observational Study [J].
Alpuente, Alicia ;
Gallardo, Victor Jose ;
Torres-Ferrus, Marta ;
Alvarez-Sabin, Jose ;
Pozo-Rosich, Patricia .
HEADACHE, 2020, 60 (04) :677-685
[2]   Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study [J].
Barbanti, Piero ;
Aurilia, Cinzia ;
Egeo, Gabriella ;
Fofi, Luisa ;
Cevoli, Sabina ;
Colombo, Bruno ;
Filippi, Massimo ;
Frediani, Fabio ;
Bono, Francesco ;
Grazzi, Licia ;
Salerno, Antonio ;
Mercuri, Bruno ;
Carnevale, Antonio ;
Altamura, Claudia ;
Vernieri, Fabrizio .
HEADACHE, 2021, 61 (02) :363-372
[3]   Trigeminal ganglion transcriptome analysis in 2 rat models of medication-overuse headache reveals coherent and widespread induction of pronociceptive gene expression patterns [J].
Buonvicino, Daniela ;
Urru, Matteo ;
Muzzi, Mirko ;
Ranieri, Giuseppe ;
Luceri, Cristina ;
Oteri, Claudia ;
Lapucci, Andrea ;
Chiarugi, Alberto .
PAIN, 2018, 159 (10) :1980-1988
[4]   Erenumab for the preventive treatment of chronic migraine complicated with medication overuse headache: an observational, retrospective, 12-month real-life study [J].
Cainazzo, Maria Michela ;
Baraldi, Carlo ;
Ferrari, Anna ;
Lo Castro, Flavia ;
Pani, Luca ;
Guerzoni, Simona .
NEUROLOGICAL SCIENCES, 2021, 42 (10) :4193-4202
[5]   Complete detoxification is the most effective treatment of medication-overuse headache: A randomized controlled open-label trial [J].
Carlsen, Louise Ninett ;
Munksgaard, Signe Bruun ;
Jensen, Rigmor Hojland ;
Bendtsen, Lars .
CEPHALALGIA, 2018, 38 (02) :225-236
[6]   Early outcomes of migraine after erenumab discontinuation: data from a real-life setting [J].
De Matteis, Eleonora ;
Affaitati, Giannapia ;
Frattale, Ilaria ;
Caponnetto, Valeria ;
Pistoia, Francesca ;
Giamberardino, Maria Adele ;
Sacco, Simona ;
Ornello, Raffaele .
NEUROLOGICAL SCIENCES, 2021, 42 (08) :3297-3303
[7]   Response Predictors in Chronic Migraine: Medication Overuse and Depressive Symptoms Negatively Impact Onabotulinumtoxin-A Treatment [J].
di Cola, Francesca Schiano ;
Caratozzolo, Salvatore ;
Liberini, Paolo ;
Rao, Renata ;
Padovani, Alessandro .
FRONTIERS IN NEUROLOGY, 2019, 10
[8]   Medication-overuse headache: risk factors, pathophysiology and management [J].
Diener, Hans-Christoph ;
Holle, Dagny ;
Solbach, Kasja ;
Gaul, Charly .
NATURE REVIEWS NEUROLOGY, 2016, 12 (10) :575-583
[9]   Unilateral pain and shorter duration of chronic migraine are significant predictors of response to onabotulinumtoxin A [J].
Dominguez, C. ;
Pozo-Rosich, P. ;
Leira, Y. ;
Leira, R. .
EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 (04) :E48-E48
[10]   OnabotulinumtoxinA in chronic migraine: predictors of response. A prospective multicentre descriptive study [J].
Dominguez, C. ;
Pozo-Rosich, P. ;
Torres-Ferrus, M. ;
Hernandez-Beltran, N. ;
Jurado-Cobo, C. ;
Gonzalez-Oria, C. ;
Santos, S. ;
Monzon, M. J. ;
Latorre, G. ;
Alvaro, L. C. ;
Gago, A. ;
Gallego, M. ;
Medrano, V. ;
Huerta, M. ;
Garcia-Alhama, J. ;
Belvis, R. ;
Leira, Y. ;
Leira, R. .
EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 (02) :411-416